 SARASOTA, Fla., March 30, 2021 PRNewswire -- INVO Bioscience, Inc. Nasdaq: INVO, a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell, the worlds only in vivo Intravaginal Culture System, today announced financial results for the year ended December 31, 2020. 